Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ganstigmine. Chiesi.

Anthony Johnson1

  • 1Anthony Johnson Consulting, Durham Close, Sawbridgeworth, Hertfordshire, CM21 0HD, UK. johnson@ntlworld.com

Current Opinion in Investigational Drugs (London, England : 2000)
|November 19, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neonatal Survival After Serial Amnioinfusions for Anhydramnios Due to Fetal Kidney Failure: The RAFT Clinical Trial.

JAMA·2026
Same author

The Solomon Technique and Extreme Preterm Birth after Laser Surgery for Twin-Twin Transfusion Syndrome.

Fetal diagnosis and therapy·2026
Same author

Premature Rupture of Membranes after Serial Amnioinfusions in Fetuses with Early Anhydramnios due to Severe Renal Disease/Lower Urinary Obstruction.

Fetal diagnosis and therapy·2026
Same author

Fetal Intervention for Giant Chorangioma with Prenatal Ductus Arteriosus Closure: A Case Report.

Fetal diagnosis and therapy·2026
Same author

Single Ventricle Physiology May Not Preclude Cardiac Repair in the Setting of Congenital Diaphragmatic Hernia.

World journal for pediatric & congenital heart surgery·2026
Same author

Feasibility, safety and outcomes of a virtual ward with remote monitoring for patients awaiting urgent coronary artery bypass graft surgery.

Open heart·2026
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Ganstigmine is a potential treatment for neurodegenerative and cognitive disorders, including Alzheimer's disease. Clinical trials were underway in the early 2000s to assess its efficacy.

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Neurodegenerative diseases and cognitive disorders pose significant health challenges.
  • Alzheimer's disease (AD) is a leading cause of dementia, characterized by progressive cognitive decline.

Purpose of the Study:

  • To evaluate Ganstigmine (CHF-2819) as a therapeutic agent for neurodegenerative and cognitive disorders.
  • To investigate the potential of Ganstigmine in treating senile dementia associated with Alzheimer's disease.

Main Methods:

  • Phase IIa clinical studies were conducted in the United States.
  • Phase IIb clinical trials were planned and initiated in patients with Alzheimer's disease.

Main Results:

  • Ganstigmine was in Phase IIa studies for Alzheimer's disease by mid-2000.

Related Experiment Videos

  • Phase IIb trials were scheduled for early 2001 and were ongoing in 2002, indicating continued development and investigation.

    • Conclusions:

    • Ganstigmine demonstrated potential as a treatment for cognitive disorders.
    • Ongoing clinical trials in the early 2000s suggested continued development for Alzheimer's disease therapy.